### **Overview** ERIS Lifesciences Ltd, established in 2007, is India's only publicly listed pharmaceutical company focused exclusively on the **domestic branded formulations** market. Ranked 20th in the Indian Pharmaceutical Market (IPM), it is the **youngest among India’s top 20 pharma companies**. The company has evolved from a specialty-focused entity into a **"Specialty plus Super-Specialty" player**, with robust capabilities in chronic and sub-chronic therapies backed by a fully integrated, vertically aligned business model. --- ### **Financial & Business Highlights** - **Annual Revenues (FY25):** ~INR 2,894 crore in Domestic Branded Formulations (DBF) - **EBITDA > INR 1,000 crore**, reflecting strong profitability and operational efficiency - **Top 25 mother brands account for ~63–70% of revenue**, with 5 generating >INR 100 crore, 6 in the INR 70–100 crore range, and 4 in the INR 50–70 crore bracket - **Revenue Diversification:** Transitioned from 80% reliance on flagship therapies (Diabetes, CVD, VMN) to a balanced mix, with **emerging segments now contributing 40% of revenue** - **Invested ~INR 4,000 crore (2022–25)** across M&A, R&D, and new manufacturing facilities, enabling strategic expansion --- ### **Core Therapeutic Areas** #### **1. Diabetes Care (31% of FY25 Revenue) – Flagship Segment** - **#5 Rank** in overall diabetes market (revenue & prescriptions); **#5 in Oral Hypoglycemic Agents (OHA)** - Strong portfolio across: - **DPP4 Inhibitors:** *Zomelis (Vildagliptin)* – **#1 generic**, growing rapidly - **SGLT2 Inhibitors:** *Gluxit (Dapagliflozin)* – **#4 among generics**, growing at 25% YoY - **Insulins:** *Xsulin (RHI), Xglar (Glargine), plus acquired brands Basalog and Insugen* - Expanded **injectables presence** (~9% of total revenue), entering GLP-1 market with **Erly (Liraglutide)** and planning **Semaglutide (FY27)** - **Diabesity strategy:** Developing novel combinations (e.g., Dapagliflozin + Metoprolol) and preparing for insulin cartridge manufacturing (Bhopal) to benefit from innovator exit in RHI cartridges - **Anti-Diabetes franchise grew 1.6x faster than the market (FY15–FY25)** #### **2. Cardiac Care (16% of Revenue) – Second Largest** - **#7 in prescriptions**, **#12 in revenue** among cardiologists - Key brands: *Eritel, Olmin, LNBloc, Crevast, Atorsave* - Achieved **9% 10-year CAGR (FY15–FY25)**, in line with market - Launch of **first-in-market combinations**: *Natribeta (Dapagliflozin + Metoprolol)* and *Gluxit Beta (Dapagliflozin + Bisoprolol)* #### **3. VMN (Vitamins, Minerals, Nutrients) – Third Largest** - Key brands: *Renerve, Remylin, Tayo* – driving double-digit growth - **#2 in Methylcobalamin combinations**, **#1 in Ginkgo Biloba (38% market share)**, **#6 in Cholecalciferol** - Focused on premiumization, novel delivery systems (PFS), and immunity-focused products like **ZAC D** #### **4. Emerging & Super-Specialty Segments (40% of Revenue)** | Segment | FY25 Revenue | Growth (YoY) | Key Brands/Initiatives | |------------------|-------------|--------------|------------------------| | **Dermatology** | ₹3,756 Cr (12%) | +23% | Acquired Oaknet, Glenmark & Biocon brands; **#2 in dermatology prescriptions**, **#5 in revenue** | | **Critical Care**| ₹1,192 Cr (4%) | **+37%** | Driven by Biocon acquisition; brands *Biopiper, Prolop, Cegava* | | **Nephrology** | ₹1,079 Cr (3%) | **+45%** | Entry via Biocon; brands *Renodapt, Tacrograf*; strong in transplant segment | | **CNS** | ₹1,571 Cr (5%) | +6% | #4 in prescriptions; launched *Baga GRS* | | **Oncology** | ₹349 Cr (1%) | N/A | Key biosimilars: *Biomab (Nimotuzumab), Hertraz, Canmab (Trastuzumab), Krabeva, Abevmy (Bevacizumab)* | > **Emerging therapies now represent ~40% of revenue**, growing at significantly faster rates than traditional segments. --- ### **Strategic Acquisitions (2022–2024)** ERIS has executed a disciplined **"String of Pearls" acquisition strategy** to build scale and enter high-growth, defensible markets. | Acquisition | Date | Key Impact | |-----------|------|-----------| | **Oaknet Healthcare (Dermatology)** | May 2022 | Foundation for derma business; EBITDA margin expanded from 10% to **~35% in FY24** | | **Swiss Parenterals (Injectables)** | Feb 2024 | EU-GMP facilities in Ahmedabad; platform for **sterile injectables**, international expansion | | **Biocon’s India Branded Formulations** | Apr 2024 | Expanded **Insulins, Oncology, Critical Care, Nephrology**; added **INR 360–386 crore in revenue** in first year | | **Chemman Labs (Bhopal)** | Aug 2024 | Now “Eris BioNxt” – **EU-GMP approvable biologics fill-finish** facility | --- ### **Manufacturing & R&D Capabilities** - **Six globally accredited manufacturing units** in **Ahmedabad, Bhopal, Chennai, Guwahati, and Gujarat**, producing: - Oral solids, liquids, softgels - Sterile injectables (SVP, LVP, PFS, lyophilized) - Biologics (insulins, GLP-1s, mAbs, rDNA products) - **EU-GMP compliance** and approvals from PIC/S, ANVISA, TGA - **2025–2028 Milestones:** - Insulin cartridge production (Bhopal): **Q3 FY26** - Recombinant Semaglutide development (Levim) - Commercialization of **biologics from Chennai (Levim) and Bhopal (Eris BioNxt)** #### **R&D Strengths** - **Ahmedabad R&D center:** 11,000 sq. ft., over 40 scientists - Focus: **First-in-market fixed-dose combinations (FDCs)**, **Novel Drug Delivery Systems (NDDS)**, and biosimilars - **Active pipeline:** - 25+ **oral solid dose combinations** (10+ targeted for FY26) - 6 **biologics candidates** (insulin analogs, GLP-1 agonists, and combos) - Triple FDCs (e.g., Dapagliflozin + Sacubitril/Valsartan + Bisoprolol) --- ### **Commercial & Market Strategy** - **Sales Force:** Over **2,600 medical representatives**, with dedicated teams for: - **Diabesity, IVF (Eris BioART: 35–40 MFRs)**, **Critical Care**, **Oncology** - **Patient Care Initiatives (PCI):** Differentiated engagement model with KOLs; delivers **ABPM, Holter, CGM services** to enhance treatment adherence - **Doctor Engagement:** Strong positioning among specialists — **#2 among dermatologists, #5 among diabetologists, #7 among cardiologists** --- ### **International Expansion (2025–2030)** - **Swiss Parenterals** is the **global arm** with commercial presence in: - **Latin America (Mexico, Chile, Peru, Argentina)** - **SE Asia, North & East Africa, CIS** - **Key Growth Drivers:** - **CDMO Platform (Eris-EU CDMO):** Offering contract development & manufacturing **in injectables and oral solids** to EU and innovator clients; **>1,000 dossiers approved or filed** - **Oral Solid Exports (OSD):** From Eris-AMD unit to RoW, PIC/S, and LatAm markets — beginning in **H2 FY26** - **B2C Exports:** Launching injectables, oral solids, and dermatology products in select markets - **FY30 Target:** International business to reach **₹1,000 crore**, driven by 3 **Strategic Business Units:** 1. Row Injectables 2. Row OSD 3. EU CDMO --- ### **Growth Strategy** ERIS is executing a **three-pillar growth strategy**: 1. **Domestic Leadership** in super-specialty therapies (Nephro, Oncology, Critical Care) 2. **Biologics Platform (Large Molecules):** Building **end-to-end capabilities** via Eris BioNxt (Bhopal), Levim (Chennai), and Swiss facilities 3. **Geographical Diversification:** Transition from **"India-only" to "India + Rest of World"**, targeting **doubling international revenue by FY28**